Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Caster, Ola; Edwards, I.
• Is Part Of: BMC neurology. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 23
• Publication Date: 2015-12
• Subjects: Glucocorticoids -- Corticosteroids -- MS -- Neurology -- Neuropathy -- Demyelinating diseases -- Pharmacoepidemiology -- Pharmacovigilance -- Clinical epidemiology -- Decision analysis; Neurology -- Periodicals; 616.8005
• DOI: 10.1186/s12883-015-0450-x
• Languages: English
• ISSNs: 1471-2377

Abstract

Abstract Background High-dose short-term methylprednisolone is the recommended treatment in the management of multiple sclerosis relapses, although it has been suggested that lower doses may be equally effective. Also, glucocorticoids are associated with multiple and often dose-dependent adverse effects. This quantitative benefit-risk assessment compares high- and low-dose methylprednisolone (at least 2000 mg and less than 1000 mg, respectively, during at most 31 days) and a no treatment alternative, with the aim of determining which regimen, if any, is preferable in multiple sclerosis relapses. Methods An overall framework of probabilistic decision analysis was applied, combining data from different sources. Effectiveness as well as risk of non-serious adverse effects were estimated from published clinical trials. However, as these trials recorded very few serious adverse effects, risk intervals for the latter were derived from individual case reports together with a range of plausible distributions. Probabilistic modelling driven by logically implied or clinically well motivated qualitative relations was used to derive utility distributions. Results Low-dose methylprednisolone was not a supported option in this assessment; there was, however, only limited data available for this treatment alternative. High-dose methylprednisolone and the no treatment alternative interchanged as most preferred, contingent on the risk distributions applied for serious adverse effects, the assumed level of risk aversiveness in the patient population, and the relapse severity. Conclusions The data presently available do not support a change of current treatment recommendations. There are strong incentives for further clinical research to reduce the uncertainty surrounding the effectiveness and the risks associated with methylprednisolone in multiple sclerosis relapses; this would enable better informed and more precise treatment recommendations in the future.